Literature DB >> 28056460

Cerebrospinal Fluid Biomarker-Based Diagnosis of Sporadic Creutzfeldt-Jakob Disease: A Validation Study for Previously Established Cutoffs.

Franc Llorens1, André Karch, Ewa Golanska, Matthias Schmitz, Peter Lange, Beata Sikorska, Pawel P Liberski, Inga Zerr.   

Abstract

BACKGROUND: Several biomarkers have been proposed to discriminate sporadic Creutzfeldt-Jakob disease (sCJD) from other dementias and control cases. However, their clinical accuracy depends on the PRNP codon 129 genotype, leaving it unclear how well established markers behave in untested conditions.
METHODS: We analyzed 14-3-3, tau, p-tau levels, and the p-tau/tau ratio in a population sample collected from Polish hospitals including nondementia, dementia, and definite sCJD cases and validated their parameters according to previously established cutoffs. Additionally, the correlation between biomarkers and disease duration as well as the influence of the PRNP129 polymorphism are reported.
RESULTS: The tau levels and p-tau/tau ratios differed considerably between sCJD and clinically characterized non-CJD cases (p < 0.001). p-tau was only elevated in sCJD when compared to cases without dementia (p < 0.05). Tau and the p-tau/tau ratio showed a sensitivity of 95 and 100%, respectively, in detecting sCJD cases. A negative correlation between tau levels and disease duration, but not the timing of lumbar puncture was observed.
CONCLUSION: The present findings confirmed the value of the p-tau/tau ratio as a robust sCJD biomarker and suggest a role for tau as prognostic marker.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28056460     DOI: 10.1159/000454802

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  9 in total

1.  Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases.

Authors:  Anna Villar-Piqué; Matthias Schmitz; Ingolf Lachmann; André Karch; Olga Calero; Christiane Stehmann; Shannon Sarros; Anna Ladogana; Anna Poleggi; Isabel Santana; Isidre Ferrer; Eva Mitrova; Dana Žáková; Maurizio Pocchiari; Inês Baldeiras; Miguel Calero; Steven J Collins; Michael D Geschwind; Raquel Sánchez-Valle; Inga Zerr; Franc Llorens
Journal:  Mol Neurobiol       Date:  2018-07-30       Impact factor: 5.590

Review 2.  Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease.

Authors:  Peter Hermann; Brian Appleby; Jean-Philippe Brandel; Byron Caughey; Steven Collins; Michael D Geschwind; Alison Green; Stephane Haïk; Gabor G Kovacs; Anna Ladogana; Franc Llorens; Simon Mead; Noriyuki Nishida; Suvankar Pal; Piero Parchi; Maurizio Pocchiari; Katsuya Satoh; Gianluigi Zanusso; Inga Zerr
Journal:  Lancet Neurol       Date:  2021-03       Impact factor: 44.182

3.  YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias.

Authors:  Franc Llorens; Katrin Thüne; Waqas Tahir; Eirini Kanata; Daniela Diaz-Lucena; Konstantinos Xanthopoulos; Eleni Kovatsi; Catharina Pleschka; Paula Garcia-Esparcia; Matthias Schmitz; Duru Ozbay; Susana Correia; Ângela Correia; Ira Milosevic; Olivier Andréoletti; Natalia Fernández-Borges; Ina M Vorberg; Markus Glatzel; Theodoros Sklaviadis; Juan Maria Torres; Susanne Krasemann; Raquel Sánchez-Valle; Isidro Ferrer; Inga Zerr
Journal:  Mol Neurodegener       Date:  2017-11-10       Impact factor: 14.195

4.  Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease.

Authors:  Franc Llorens; Niels Kruse; André Karch; Matthias Schmitz; Saima Zafar; Nadine Gotzmann; Ting Sun; Silja Köchy; Tobias Knipper; Maria Cramm; Ewa Golanska; Beata Sikorska; Pawel P Liberski; Raquel Sánchez-Valle; Andre Fischer; Brit Mollenhauer; Inga Zerr
Journal:  Mol Neurobiol       Date:  2017-03-21       Impact factor: 5.590

5.  No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis.

Authors:  Joery Goossens; Maria Bjerke; Hanne Struyfs; Ellis Niemantsverdriet; Charisse Somers; Tobi Van den Bossche; Sara Van Mossevelde; Bart De Vil; Anne Sieben; Jean-Jacques Martin; Patrick Cras; Johan Goeman; Peter Paul De Deyn; Christine Van Broeckhoven; Julie van der Zee; Sebastiaan Engelborghs
Journal:  Alzheimers Res Ther       Date:  2017-07-14       Impact factor: 6.982

6.  Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum.

Authors:  Lieke H H Meeter; Everard G Vijverberg; Marta Del Campo; Annemieke J M Rozemuller; Laura Donker Kaat; Frank Jan de Jong; Wiesje M van der Flier; Charlotte E Teunissen; John C van Swieten; Yolande A L Pijnenburg
Journal:  Neurology       Date:  2018-03-07       Impact factor: 9.910

7.  Total and Phosphorylated Cerebrospinal Fluid Tau in the Differential Diagnosis of Sporadic Creutzfeldt-Jakob Disease and Rapidly Progressive Alzheimer's Disease.

Authors:  Peter Hermann; Philip Haller; Stefan Goebel; Timothy Bunck; Christian Schmidt; Jens Wiltfang; Inga Zerr
Journal:  Viruses       Date:  2022-01-28       Impact factor: 5.048

Review 8.  Role of Biomarkers for the Diagnosis of Prion Diseases: A Narrative Review.

Authors:  Miren Altuna; Iñigo Ruiz; María Victoria Zelaya; Maite Mendioroz
Journal:  Medicina (Kaunas)       Date:  2022-03-25       Impact factor: 2.948

9.  CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD.

Authors:  Natalia Ermann; Piotr Lewczuk; Matthias Schmitz; Peter Lange; Tobias Knipper; Stefan Goebel; Johannes Kornhuber; Inga Zerr; Franc Llorens
Journal:  Ann Clin Transl Neurol       Date:  2018-05-26       Impact factor: 4.511

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.